Chronic inflammation is a persistent, dysregulated immune response that gradually damages tissues and alters organ function. At its core, chronic inflammation differs from acute inflammation by its duration and by the balance of immune signals that favor prolonged activation instead of rapid resolution. This sustained activity is driven by immune cells, soluble mediators, and local tissue responses that together create a self-perpetuating state with systemic consequences.
Biological mechanisms
Key mediators include cytokines such as interleukin 1, interleukin 6, and tumor necrosis factor alpha, which orchestrate immune cell recruitment, vascular changes, and metabolic shifts. Charles A. Dinarello at the University of Colorado has documented the central role of interleukin 1 in sustaining inflammatory cascades and promoting fever, tissue remodeling, and metabolic disturbance. Persistent cytokine exposure fosters reactive oxygen species production and genomic stress, increasing mutation risk and promoting cellular senescence, where senescent cells secrete proinflammatory factors that reinforce local inflammation. Immune cell phenotypes also shift over time; macrophages and T cells move from reparative roles toward chronic tissue-destructive states. These mechanisms explain how long-term inflammation can be both a driver and consequence of injured tissues.
Disease relevance and clinical evidence
Chronic inflammation contributes to common diseases across systems. In cardiovascular disease, inflammation participates in plaque formation, destabilization, and thrombosis. Paul M. Ridker at Brigham and Women's Hospital and Harvard Medical School led clinical research demonstrating that targeting the inflammatory cytokine interleukin 1 beta can lower the risk of recurrent cardiovascular events independent of lipid lowering, providing direct human evidence that inflammation is causal rather than merely associated. In oncology, sustained inflammatory signaling can promote tumor initiation, angiogenesis, and immune evasion. In metabolic disease, inflammatory mediators impair insulin signaling and lipid handling, linking inflammation to type 2 diabetes and nonalcoholic fatty liver disease. In the aging process, chronic low-grade inflammation underlies frailty and multimorbidity; Claudio Franceschi at the University of Bologna coined and developed the concept of inflammaging to describe how lifelong immune activation shapes vulnerability to age-related disorders.
Consequences extend beyond organ damage to altered physiology and population health patterns. Chronic inflammation raises susceptibility to infection in some contexts by exhausting immune reserves, while in others it exaggerates responses to triggers such as air pollution or psychosocial stress. Environmental and cultural factors modulate risk: diets high in processed foods, persistent exposure to urban particulate matter, and socioeconomic stressors can increase inflammatory burden, while traditional dietary patterns and community practices may be protective. Territorial differences in infectious disease exposure also shape immune set points so that the same inflammatory marker may carry different implications across populations.
Interventions that reduce chronic inflammation can modify disease trajectories, but benefits and risks are context-dependent. Anti-inflammatory therapies may lower some disease risks while increasing susceptibility to infection. Lifestyle approaches that reduce inflammatory drivers, including improved diet, physical activity, tobacco avoidance, and reduction of environmental exposures, remain foundational and accessible strategies that work alongside targeted biomedical therapies to mitigate the wide-ranging harms of chronic inflammation.